Pharmaceutical Executive-05-01-2012

Marooned at the Top

The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.

Will changes to the P&R system in the UK finally put some real metrics behind the elusive concept of value?

More consolidation didn't boost sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.

In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory.

Companies know they need regulatory information management. What they don't always know is where to start and how to weave this vital capability across the enterprise.

Options for using data have proliferated to the point of becoming overwhelming. So what opportunities does this information explosion present?

In late March, the Supreme Court debated the merits-or lack thereof-of the Obama Administration's Patient Protection and Affordable Care Act. Can you match the analogy with the Justice?

To gain market access in emerging markets, pharma companies face pressure to offer a convincing Corporate Value Proposition to governments.

Data has become as important as the drug in driving success in healthcare.

Highlighting the companies awarded for exemplifying a high level of operational excellence with technology.